Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer

Inclusion Criteria

• •Have biopsy proven adenocarcinoma of the prostate (no small cell, sarcomatoid, or other rare subtypes)
• •Be planning a course of at least 5 months of androgen deprivation therapy. Patients who have had androgen deprivation therapy in the past as part of salvage therapy or primary therapy, but are initiating a new course will be eligible.
• •Have a testosterone concentration within normal limits.
• •No neoadjuvant hormonal or chemotherapy (other clinical trials) for their prostate cancer
• •Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• •Have blood, urea, nitrogen (BUN)/creatinine (Cr), liver enzymes, complete blood count (CBC), and prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) within normal limits
• •Voluntarily agree to participate and a sign an informed consent document
• •Agree to have prostate biopsy blocks provided to the study for evaluation
• •Willing to discontinue all current vitamin/mineral supplements
• •Not currently be taking complementary or alternative products (i.e. PC-SPES, Saw Palmetto) that target the prostate or may impact the hormonal environment
• •Agree to consume a standardized vitamin and mineral supplement (provided by the study) and avoid other nutrition, dietary, or alternative medications/supplements for the duration of the study